natgillin/translations-raw huggingface dataset:
The crystalline structure as defined in Claim 6 characterized by one or more of the following: 
Kristalna struktura kako je definirano u zahtjevu 6 naznačena time da ima jedno ili više od slijedećeg: a)
An isolated antibody or fragment thereof that is capable of binding to a complex comprising B-Klotho and FGFR1c and induces FGF21-mediated signaling, wherein said isolated antibody or fragment thereof comprises an amino acid sequence 90% identical to SEQ ID NO: 50 and comprises an amino acid sequence 90% identical to SEQ ID NO: 68 for use in therapy. 
CDRL3: SEQ ID NO: 188. Izolirano antitijelo ili njegov fragment koje je sposobno za vezanje za kompleks koji sadrži B-Klotho i FGFR1c i inducira FGF21-posredovani prijenos signala, pri čemu navedeno izolirano antitijelo ili njegov fragment sadrži aminokiselinsku sekvencu 90% identičnu sa SEQ ID NO: 50 i sadrži aminokiselinsku sekvencu 90% identičnu sa SEQ ID NO: 68.
stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein: RN is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R12; m and n, which may be the same or different, are each an integer of f 0, 1, 2, or 3; 
(ID ili njegovog stereoizomera, ili njegove farmaceutski prihvatljive soli, pri čemu: R, je odabran iz niza koji čine vodik, alkil, alkenil, alkinil, cikloalkil, heterociklil, aril, 1 heteroaril, pri čemu je svaki alkil, alkenil, alkinil, cikloalkil, heterociklil, aril, i heteroaril neovisno proizvoljno supstituiran s barem jednim supstituentom R'*; tje broj od 0, 1, 2, ili 3;
a DNA-targeting segment comprising a nucleotide sequence that is 15 nucleotides (nt) to 25 nt long and is complementary to a target sequence in a target DNA molecule; and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK; i
Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. 
Chem., 1977, 20, 243-249, analog A farnezil difosfata i analoge preskvalen pirofosfata (PSQ-PP) kao što su naveli Corey and Volante, J.
Y- is selected from the group consisting of 
Y- se izabire iz skupine koja obuhvaća [image]
The instrument of Claim 1, wherein a proximal end (116) of the infusion/aspiration tip (104) comprises a bore and wherein the distal end (124) of the aspiration tube (108) is received into the bore. 
Instrument prema zahtjevu 1, naznačen time, da bliži kraj (116) od infuzijskog/aspiracijskog vrha (104) sadrži TUpu i pritom se distalni kraj (124) aspiracijske cjevčice (108) prihvaća u tu rupu.
The formulation of any one of claims 1 to 4 for use in treating a disease or disorder in a human subject, wherein said formulation is in an amount effective to treat the disease or disorder. 
5. = Formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što je namijenjena upotrebi u liječenju bolesti ili poremećaja kod ljudskog subjekta, gdje je navedena formulacija u količini djelotvornoj za liječenje bolesti ili poremećaja.
Coating composition according to claim 1, characterised in that said coating composition has a PVC of from 10 to 30 vol.-%, preferably 15 to 25 vol.-%, more preferably 17 to 21 vol.-%, e.g. 19 vol.-%. 
Smjesa za premazivanje u skladu s patentnim zahtjevom 1, naznačena time što navedena smjesa za premazivanje ima PVC od 10 do 30 vol-%, po mogućnosti 15 do 25 vol-%, poželjnije 17 do 21 vol-%, primjerice 19 vol-%.
It has been found that for the purposes of the present invention it is decisive that the flow of material or “mass flow” as defined above, has a high value in order to ensure temperatures and speed required by the rolling process for an end product having the desired values of thickness and of surface and inner quality and that the thickness reduction is increasing from the mould on. 
Otkriveno je da je za potrebe predstavljenog izuma odlučujuće da protok materijala ili "maseni protok" kako je gore definiran, bude visoke vrijednosti kako bi se osigurale temperature i brzine potrebne za postupak valjanja za završni proizvod željenih vrijednosti debljine, kvalitete površine i unutarnje kvalitete, 1 da se smanjenje debljine povećava od slaba nadalje.
Likewise, incorporated U.S. Pat. 
US (73) Nositelj patenta:
The method of claim 1, wherein the concentration of the fexinidazole metabolites exceeds 10 ng/mL for at least 1 hour during each day of the course of fexinidazole administration. 
= Feksinidazol za uporabu prema zahtjevu 1, naznačen time, da je količina feksinidazola koja se primjenjuje, dovoljna za proizvodnju koncentracije feksinidazola u plazmi, koja barem u roku od jednoga sata prelazi 10 ng/mL., svakoga dana u ciklusu primjene feksinidazola.
In accordance with another preferred embodiment the suspension element may comprise one of the following: mounting lug, a single hook, a double hook, a catch or a combination thereof. 
U skladu s drugom preferiranom izvedbom ovjesni element može sadržavati jedno od slijedećeg: montažnu ušku, pojedinačnu kuku, dvostruku kuku, kvaku ili njihovu kombinaciju.
Method for decoding an image by using large transformation units 
UREĐAJ ZA DEKODIRANJE SLIKE KORIŠTENJEM VELIKIH TRANSFORMACIJSKIH JEDINICA
A combination according to claim 1 or 2, wherein the B2 agonist is a long-acting B2 agonist. 
Kombinacija sukladno patentnom zahtjevu 1 ili 2, naznačena time, da je B2 agonist dugo-djelujući fB 2 agonist.
Transporter construct according to claim 1, wherein the transporter construct comprises at least one sequence according to rXXXrXXXr, wherein: r represents an D-enantiomeric arginine; 
Transportni konstrukt prema zahtjevu 1, naznačen time da transportni konstrukt sadrži barem jednu sekvencu u skladu sa rXXXrXXXr, pri čemu: r predstavlja D-enantiomerni arginin;
Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with t-butyl; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Aaa aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je C-kraj slobodni kraj.
The immunogenic composition of claim 7 wherein the H. influenzae b capsular saccharide is conjugated to a carrier protein selected from the group consisting of TT, DT, CRM197, fragment C of TT and protein D. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što saharid Hib je konjugiran s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRMI197, C fragment proteina TT, protein D, OMPC i pneumolizin.
Process for preparing crystallized form 1 hydrogen sulfate of clopidogrel from a solution of hydrogen sulfate of clopidogrel in a solvent, wherein the solvent is 
Postupak dobivanja kristaliziranog oblika 1 hidrogensulfata klopidogrela iz otopine hidrogensulfata klopidogrela u otapalu, naznačen time što navedeno otapalo je
The formulation according to claim 8, wherein the antibody is the humanized anti-IL-6 receptor antibody MRA, the concentration of arginine is 50 to 700 mM, the concentration of methionine is 10 to 100 mM, the amount of polysorbate 80 as the surfactant is 0.005 to 3% (w/v), the concentration of the histidine buffer solution is 5 to 100 mM, and the concentration of the antibody is 100 to 300 mg/ml. 
Formulacija prema zahtjevu 8, naznačena time da protutijelo je humanizirano anti-IL-6 receptorsko protutijelo MRA, koncentracija arginina je 50 do 700 mM, koncentracija metionina je 10 do 100 mM, količina polisorbata 80 kao surfaktanta je 0.005 do 3% (t/v), koncentracija histidinske puferske otopine je 5 do 100 mM, a koncentracija protutijela je 100 do 300 mg/ml.
It is further preferred that the particle sizes of the other excipients used in the pharmaceutical compositions of the present invention are within the range of D90<500 µm, preferably D90<350 µm, in order to ensure homogeneity of the compression mixture and homogeneous granulation and compression. 
Nadalje, poželjno je da veličina čestica drugih ekscipijensa korištenih u farmaceutskim pripravku ovog izuma bude unutar raspona od D90 < 500 um, poželjnije D90 < 350 um, kako bi se na taj način omogućila homogenost kompresijske mješavine i homogena granulacija te kompresija.
where a fluid supply valve is located between the system valves and adapted to allow inflow of a fluid when the system valves and the drain valve are closed; 
- gdje se ventil za dovod fluida nalazi između sustavnih ventila 1 prilagođen je da omogući dotok fluida kada su sustavni ventili i ispusni ventil zatvoreni;
1, in a second operative configuration; FIG. 3 shows a partially sectioned plan view of the device shown in FIG. 
Slika 3 - prikazuje nacrt uređaja koji je prikazan na slici 1 u položaju mirovanja; uređaj je prikazan djelomično u presjeku;
The cells were washed in PBS and resuspended in the manufacturer's Assay Buffer. 
Stanice su isprane u PBS i resuspendirane u pripremljenom Puferu za Ispitivanje.
Pharmaceutical composition comprising a VLP according to any of the above claims wherein at least 1%, preferably at least 15%, more preferably at least 50%, in particular preferred at least 95% of the total amount of drug substance (cargo) is fully encapsulated in the hull of the VLP. Pharmaceutical composition according to claim 15 wherein the VLPs are non-aggregated. Use of a VLP derived from human polyoma virus comprising a drug as a drug delivery system for the drug delivery to and/or into a microglia cell and/or a neuron. 
Farmaceutski pripravak namijenjen uporabi u postupku liječenja terapijom ili metodom in vivo dijagnosticiranjaze neurološkog poremećaja središnjeg živčanog sustava, pri čemu farmaceutski pripravak sadrži virusu sličnu česticu (VLP) prema bilo kojem od gore navedenih patentnih zahtjeva pri čemu najmanje 1%, poželjno najmanje 15%, još poželjnije najmanje 50%, u osobito poželjno 95% ukupna količina supstance lijeka (teret) je potpuno enkapsulirana u opni virusu slične čestice (VLP) 1 pri čemu je neurološki poremećaj odabran iz skupine koja obuhvaća moždani udar, ovisnost o alkoholu, Alzheimerovu bolest, anksioznost, hiperkineički
Example 4 Production of Form-II Crystal of the Invention 
Datum podnošenja europske prijave patenta:
The residue was purified by flash chromatography (SiO2) using 5% ethyl acetate-hexanes as eluant to afford 79 mg of the desired product as a 4:1 mixture of double bond regio-isomers. 
Ostatak se pročisti svjetlosnom kromatografijom (SiO») uporabom 5% etil acetat/heksana kao sredstva za eluaciju da bi se dobilo 79 mg željenog produkta kao 4:1 smjese regioizomera dvostruke veze.
contacting the reaction product with a surfactant system while the temperature of said reaction product is at least 70°C. to provide a glyphosate salt-containing composition which possesses a cloud point above at least 70°C. or no cloud point when the composition is heated to its boiling point, said surfactant system comprising: 
kontaktiranje reakcijskog produkta sa sustavom surfaktanta dok je temperatura navedenog reakcijskog produkta najmanje 70°C zbog dobivanja sastava koji sadrži sol glifosata koji ima točku zamućivanja iznad najmanje 70°C ili nema točku zamućivanja kada se sastav zagrijava do svoje točke vrenja, navedeni sustav surfaktanta sadrži:
The method of claim 25, wherein therapeutically effective amount of crenolanib or a salt thereof is provided at least one of sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed hematologic malignant proliferative disease patient, to maintain remission, or a relapsed/refractory hematologic malignant proliferative disease patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana barem jednom slijedno ili istodobno s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
Preference is given to a process for preparing the compound of the formula (II) according to the invention which is characterized in that the compound of the formula (I) is reacted in a solvent with aqueous sodium hydroxide solution, if appropriate with addition of a base. 
Postupak za pripravu spoja formule (II) prema zahtjevu 3, naznačen time da spoj s formulom (1) reagira u otapalu s vodenom otopinom natrijevog hidroksida, ako je prikladno uz dodavanje baze.
represents a hydrogen atom. 
Y* predstavlja atom vodika.
The rAAV vector according to any one of claims 1 to 11 for use in preventing, treating or ameliorating one or more symptoms of a disease, injury, disorder, trauma or dysfunction in a mammal, and further preferably for use in treating, preventing, or ameliorating one or more symptoms of cancer, diabetes, autoimmune disease, kidney disease, cardiovascular disease, pancreatic disease, intestinal disease, liver disease, neurological disease, neuromuscular disorder, neuromotor deficit, neuroskeletal impairment, neurological disability, neurosensory dysfunction, stroke, ischemia, eating disorder, a1-antitrypsin (AAT) deficiency, Batten's disease, Alzheimer's disease, Huntington's disease, Parkinson's disease, skeletal disease, trauma, or pulmonary disease in a mammal. 
rAAV vektor prema bilo kojem od zahtjeva 1 do 9 naznačen time da je za uporabu za dijagnosticiranje, prevenciju, liječenje ili ublažavanje jednog ili više simptoma bolesti, oštećenja, poremećaja, traume ili disfunkcije kod sisavaca, te dodatno poželjno za uporabu u liječenju, prevenciji, ili ublažavanju jednog ili više simptoma raka, dijabetesa, autoimune bolesti, bolesti bubrega, kardiovaskularne bolesti, bolesti gušterače, bolesti crijeva, bolesti jetre, neurološke bolesti, neuromuskularnog poremećaja, neuromotornog odstupanja, neuroskeletalnog poremećaja, neuroloških invalidnosti, neurosenzornog poremećaja, kapi, ishemije, poremećaja hranjenja, nedostatka á1-antitripsina (AAT), Battenove bolesti, Alzheimerove bolesti, Huntingtonove bolest, Parkinsonove bolesti, bolesti kostiju, ozljede ili plućne bolesti kod sisavca.
The method according to claim 18, wherein the method includes the step of applying an initial pulling force to the envelope until a portion of the envelope breaks within the outer cable sheath, prior to pulling the remaining portion of the envelope from the opposite end of the outer cable sheath. 
Postupak sukladno zahtjevu 14, uključujući korak podvrgavanja omotnice (8) vučnoj sili dok se dio omotnice ne slomi unutar vanjskog plašta (6), 1 to prije povlačenja preostalog dijela omotnice (8) iz nasuprotnog kraja vanjskog plašta (6).
Further polypeptides of interest include, e.g., erythropoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony-stimulating factor, pituitary peptide hormones, menopausal gonadotropin, insulin-like growth factors (e.g., somatomedin-C), keratinocyte growth factor, glial cell line-derived neurotrophic factor, thrombomodulin, basic fibroblast growth factor, insulin, Factor VIII, somatropin, bone morphogenetic protein-2, platelet-derived growth factor, hirudin, epoietin, recombinant LFA-3/IgG1 fusion protein, glucocerebrosidase, and muteins, fragments, soluble forms, functional derivatives, fusion proteins thereof. 
Nadalje proteini od interesa uključuju, pr. eritropoietin, stimulirajući faktor kolonija granulocita, stimulirajući faktor kolonija granulocita-makrofaga, peptidne hormone hipofize, menopauzni gonadotropin, inzulinu slične faktore rasta (pr. somatomedin-C), faktor rasta keratinocita, neurotrofični faktor glijalne stanične linije, trombomodulin, osnovni faktor rasta fibroblasta, inzulin, faktor VIII, somatropin, koštani morfogenetski protein-2, faktor rasta trombocita, hirudin, epoietin, rekombinantni LFA-3/IgG1 fuzijski protein, glukocerebrozidazu, i muteine, fragmente, topive oblike, funkcionalne derivate i fuzijske proteine od navedenog.
2, 4, 5, 6 and 7 the handle 11 comprises three longitudinally elongate flexible spines 16, 17, 18 arranged at the apexes of an isosceles triangle constructed in a plane perpendicular to the longitudinal direction L-L. 
Cetkica za zube (10), u skladu s patentnim zahtjevom 1, naznačena time što se dvije ili više prečki (16, 17, 18) sreću uz prvi i drugi kraj (12, 13) drške (11).
A hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid for use in treating or preventing diseases or disorders mediated by lymphocyte interactions according to claim 1, wherein the disease or disorder is polymyositis. 
Hemifumaratna sol od 1-(4-{1-[(E)-4-cikloheksil-3-trifluorometil-benziloksiimino]-etil}-2-etil-benzil)-azetidin-3-karboksilne kiseline prema zahtjevu 1, naznačena time, da spomenuta sol ima stupanj kristaliniteta veći od oko 20%.
blending said crude oil with the resulting liquid fuel to form a blend; and 
(d) miješanju navedene sirove nafte s dobivenim tekućim gorivom kako bi se dobilo smjesu; i
purging the alcohol dehydration chamber with an inert gas; 
- < čišćenje komore za dehidraciju alkohola propuhivanjem s inertnim plinom;
“Substituted aryl” means aryl substituted with substituted with up to 3 substituents selected from halo, —CN, —NO2, —OH, optionally halo-substituted C1-3 alkyl (e.g. 
Â« Supstituirani ari Â« znači aril supstituiran sa supstituentom sa do 3 supstituenta odabrana od halo, -CN, -NO», -OH, po izboru halo-supstituirani Cia alkil (na pr.
The bicomponent fiber of claims 1-2, wherein the first and second polymer component are independently selected from the group consisting of polyethylene terephthalate, polytrimethylene terephthalate, polybutylene terephthalate, and polylactic acid, and copolymers and combinations thereof. 
Postupak prema zahtjevu 1, naznačen time, da je polimer koji se može kristalizirati, odabran iz skupine koju čine: polietilen-tereftalat, politrimetilen-tereftalat, polibutilen-tereftalat, i polilaktička kiselina, i kopolimeri, te njihove kombinacije.
A polymorph of the crystalline form of claim 1, characterized by an X-ray power diffraction pattern including peaks at approximately 8.06, 13.02, and 18.83 °2θ using Cu Ka radiation, or peaks at approximately 8.06, 11.41, 13.02, 18.83, 20.54, and 24.53 °2θ using Cu Ka radiation, or peaks at approximately 5.60, 8.06, 8.57, 11.41, 13.02, 15.58, 18.83, 20.54 and 24.53 °2θ using Cu Ka radiation, or by an X-ray power diffraction pattern substantially similar to that set forth in Figure 8. 
Polimorf kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu sa signalima na približno 8,06, 13,02, te 18,83 °2θ uz upotrebu zračenja Cu Ka, ili signalima na približno 8,06, 11,41, 13,02, 18,83, 20,54, te 24,53 °2θ uz upotrebu zračenja Cu Ka, ili signalima na približno 5,60, 8,06, 8,57, 11,41, 13,02, 15,58, 18,83, 20,54 i 24,53 °2θ uz upotrebu zračenja Cu Ka, ili uzorak difrakcije rendgenskih zraka na prahu uglavnom sličan onom prikazanom na Slici 8.
Furthermore, the device 30 has a planing equipment 63 for the "smooth planing" of at least one surface of the respective board-like, plane pieces of wood. 
Nadalje, uređaj 30 ima uređaj za ravnanje 63, koji obavlja "glatko ravnanje" najmanje jedne površine odgovarajućih ravnih komada od drva koji imaju oblik ploče.
Typical doses may be in the range 0.5-10 mg, but doses of approximately up to 200 mg can be delivered by lozenges of the invention. 
Tipične doze mogu biti u opsegu 0.5-10 mg, ali doze od približno do 200 mg se mogu primjeniti pomoću tableta prema izumu.
from 1 to 70 wt. % of at least one aluminium(III) salt, and wherein all wt. % are relative to the total weight of the composition (T). 
od 1 do 70%, težinski, najmanje jedne aluminijeve(III) soli, te gdje su svi težinski postoci u odnosu na ukupnu težinu smjese (T).
In this embodiment, fuel element 10 may be blowpipe charcoal or a pressed or extruded carbon rod or plug or other carbonaceous fuel source. 
U ovoj realizaciji, gorivi element 10 može biti ugljik za lulu ili prešani ili istisnuti ugljični štap ili čep ili drugi izvor ugljičnog goriva.
Thus, the portion of the fuel element adjacent to the aerosol generating means becomes hot quickly, which significantly increases heat transfer to the aerosol generating means, especially during the early and middle puffs. 
Tako dio gorivog elementa koji je u blizini sa sredstvom za generiranje aerosola postaje brzo vruć što značajno povećava prijenos topline na sredstvo za generiranje aerosola, naročito za vrijeme prvih i srednjih dimova.
The thieno[3,2-d]pyrimidine compound or its pharmaceutically acceptable salt of claim 1, wherein W is NH. 
2. - Derivat tieno[3,2-dlpirimidina u skladu s patentnim zahtjevom 1, pri čemu W je NH ili njegova farmaceutski prihvatljiva sol.
The method of embodiment 30, wherein the fragment comprises residues 118-126 of alpha synuclein. The method of any of embodiments 27-31, wherein the fragment is linked to a carrier. An antibody that specifically binds to an epitope within residues 110-130 of human alpha-synuclein, residues being numbered according to SEQ ID NO: 1, for use in prophylaxis or treatment of a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, wherein the antibody competes with monoclonal antibody 9E4 for binding to human alpha-synuclein, wherein antibody 9E4 is produced by hybridoma JH17.9E4.3.37:1.14.2 deposited as ATCC accession number PTA-8221. 
Antitijelo koje se specifično veže za epitop unutar ostataka 118-126 humanog alfa-sinukleina, pri čemu su ostaci obilježeni prema SEQ ID NO: 1, za upotrebu u profilaksi ili liječenju bolesti Lewyjevog tijela (LBD) koja je izabrana od Parkinsonove bolesti, uključujući idiopatsku Parkinsonovu bolest, demenciju sa Lewyjevim tijelima (DLB), bolest difuznih Lewyjevih tijela (DLBD), varijantu Alzheimerove bolesti sa Lewyjevim tijelom (LBVAD), sindrom čiste autonomne disfunkcije, disfagiju Lewyjevih tijela, slučajnu LBD, nasljeđenu LBD, višestruku atrofiju sistema, olivopontocerebelarnu atrofiju, striatonigralnu degeneraciju i Shy-Dragerov sindrom, gde se antitijelo natječe s monoklonskim antitijelom 9EA4 za vezivanje za humani alfa-sinuklein, pri čemu se antitijelo 9E4 proizvodi od hibridoma JH17.9E4.3.37:1.14.2 deponiranog pod ATCC pristupnim brojem PTA-8221.
the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 19 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 22; the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 20 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 23; and the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 21 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 24. 
amino kiselinu varijabilnu regiju teškog lanca iznetu u SEK ID BR: 19 i sekvencu amino kiseline varijabilnu regiju teškog lanca iznetu u SEK ID BR: 22; sekvencu amino kiseline varijabilnu regiju teškog lanca iznetu u SEK ID BR: 20 i sekvencu amino kiseline varijabilnu regiju lakog lanca iznijetu u SEK ID BR: 23; i sekvencu amino kiseline varijabilnu regiju teškog lanca iznetu u SEK ID BR: 21 i sekvencu amino kiseline varijabilnu regiju lakog lanca iznetu u SEK ID BR: 24.
The method of claim 8, wherein the bacterial disease, bacterial infection or bacterial colonization is a bacterial disease, a bacterial infection or bacterial colonization of the skin or a mucous membrane, wherein the mucous membrane is of the upper respiratory tract, or of the nasal cavity. 
Kimerni polipeptid ili pripravak, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 10 do 13, naznačeni time što je bakterijska bolest, bakterijska infekcija ili koloniziranje bakterija bakterijska bolest, bakterijska infekcija ili koloniziranje bakterija na koži ili sluznici, po mogućnosti sluznici gornjeg dišnog sustava, poželjnije sluznici nosne šupljine.
The combination preparation of claim 23 for use as a medicament. 
Kombinirani pripravak iz zahtjeva 21 za uporabu kao medikament.